MYBIOPASSPORT
5.2.2021 08:50:10 CET | Business Wire | Press release
Mybiopassport.com, the platform set-up by CoreMedica Europe, a Swiss biotechnology company with their Swissmedic authorized laboratory based in Geneva, announced today the launch of their “Nutritional Profile” and “Sport Performance Profile” tests, which will complement their current “Immunity Profile” and “COVID-19” tests
Mybiopassport proposes at-home blood collection tests to help anyone become the “heroes of their own health” . Individuals can now collect only a few drops of blood at their homes and send their samples by regular prepaid mail to the company’s authorized laboratory located in Geneva, Switzerland, to determine the levels of key biomarkers known to support sport performance, a healthy nutrition, and the immune system. The tests can be ordered at www.mybiopassport.com and personalized results are delivered to each individual on the online portal through a simple sign-up procedure.
The purposes of these tests are as follows :
- Nutritional – A tool informing the client of their current nutritional status based on past habits and providing personalized recommendations on how to correct any deficiencies or excesses through nutrition. The first of its kind, this test provides information about the levels of micronutrients belonging to all four classes of essential micronutrients, namely vitamins, minerals, fatty acids and amino acids. These are all linked to specific bodily functions (fatigue, sleep, anxiety, etc.) making this test the most comprehensive and informative on the market.
- Sport Performance – A tool developed to help amateur and professional athletes determine if their performance related biomarkers are at their optimal levels to allow them to perform at their best. All the biomarkers tested are linked to specific sport related functions, such as recovery , muscle growth, energy delivery, or even as specific as exercise induced joint pain.
- Immunity - The COVID-19 & Immunity Profile, powered by Mybiopassport, lets clients know if they were previously infected by the SARS-CoV-2 virus through the development of specific antibodies. More importantly, the Immunity Profile test also delivers actionable nutritional recommendations based on a set of key biomarkers known to support the immune system, including vitamin D, zinc and magnesium.
It is now widely accepted that the first step towards a healthy body is good nutrition. Indeed, multiple studies have shown that the risks of developing cardiovascular disease, diabetes, and even dementia are strongly linked to long-term nutritional habits. Recent scientific reports and publications have highlighted the role of nutrition, optimal micronutrient status and a well-functioning immune system as a modifiable factor in reducing the risk of viral infections and their severity. These publications highlight the key role of a good nutritional status for a well-functioning immune system.
Mybiopassport’s mission is clearly to democratize access to specific health-related information and to give people the means to not only understand, but also act on their health through nutrition and lifestyle. They firmly believe in individual empowerment and that the access to personalized health information is the first step towards preventing potential health issues.
Mybiopassport relies on a unique technology in the personalized analysis of biological data on three main axes:
- Pre-analytical with the easy collection of a few drops of blood anywhere, at any time and by anyone,
- Analytical, with the measurement of an unprecedentedly large number of phenotypic biomarkers, via a unique know-how developed over several years,
- Post-analytical, providing not only a scientific result, but personalized recommendations based on a patented technology applied in several fields, such as immunity, nutrition, sport, longevity and anti-aging.
Individuals can now collect a few drops of blood from the comfort and safety of their homes and send their samples by prepaid regular mail to Mybiopassport’s laboratory in Geneva.
The Nutritional, Sport Performance and Immunity tests can be ordered at www.mybiopassport.com and personalized results are delivered to each individual on the online portal with test results reviewed by health professionals.
About CoreMedica Europe:
As a background, BioKaizen, founded in Switzerland and born from developers of the athlete biological passport to detect drug use for the World Anti-Doping Agency and the International Olympic Committee, has developed a mass spectrometry technology platform to identify a person’s nutritional profile using dried blood. Following the merger with BioKaizen in 2018 and its recent acquisition by Swiss Medical Group Holding Luxembourg SA, CoreMedica Europe expanded its offering globally to include personalized nutrition and sport performance information that empowers customers with information to help actively manage their health.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210204006231/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 13:43:00 CEST | Press release
For Trade and Medical Media Only The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs) Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs) Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing a
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 13:00:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415938477/en/ Photo credit: Jos Schmid, Photographer
tesa Selects Kinaxis as the Digital Backbone for Global Integrated Business Planning Transformation27.4.2026 13:00:00 CEST | Press release
Kinaxis Maestro™ platform to serve as the foundation for a multi‑year transformation to resilient, globally orchestrated planning ecosystem Kinaxis® (TSX: KXS), a global leader in end‑to‑end supply chain orchestration, today announced that tesa SE, a global manufacturer of adhesive tapes and self-adhesive product solutions, has selected the Kinaxis Maestro™ platform as a core enabler of its global, multi‑year supply chain and integrated business planning (IBP) transformation. Following an extensive evaluation, tesa selected Kinaxis to support its evolution from regionally fragmented planning practices toward a centrally governed, globally orchestrated IBP operatingmodel. Kinaxis will support tesa in improving enterprise-wide transparency, strengthening resilience, and enabling faster, more informed decision making across an increasingly complex and volatile global supply chain network. With 130 years of innovation, tesa is one of the world’s leading manufacturers of adhesive tapes and
70% of Enterprise AI is Uncontrolled, Driving Hidden Risk, Cost and Slower ROI27.4.2026 10:00:00 CEST | Press release
Lenovo research highlights a growing AI execution gap as organizations struggle to control and operate AI across their environments AI is already being used across your organization, whether it has been formally approved or not. Employees are using AI with or without IT involvement, fueling the rise of ‘shadow AI’ across the enterprise, creating gaps in governance and control. This is no longer just an IT challenge. For Chief Information Security Officers, this shift is expanding the attack surface across devices, endpoints, and data flows, introducing unmanaged risk and increasing the likelihood of sensitive company data being exposed or accessed without proper controls. What this reveals is a growing AI execution gap: usage is accelerating, but control is not keeping pace. Based on a survey of 6,000 employees worldwide, Lenovo’s latest Work Reborn Report, Leading Your Workforce to Triumph with AI, finds that more than 70% of employees are using AI weekly, with up to one third operati
First Enterprise Quantum Computer Purchase in Japan: IQM to Deploy System to TOYO Corporation27.4.2026 08:00:00 CEST | Press release
First enterprise quantum computer purchase in Japan cements IQM's position as the global leader in deployed quantum computers The Radiance 20-qubit system will enable TOYO to explore various industry use cases, while advancing a hybrid quantum-HPC infrastructure. This will be the third quantum computer to be deployed by IQM in the Asia-Pacific region. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the purchase of its full-stack 20-qubit quantum computer by TOYO Corporation, marking the first enterprise quantum system deployment in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426053944/en/ (From Left): Toshiya Kohno, Representative Director, President and CEO of TOYO Corporation, and Jan Goetz, CEO & Co-founder of IQM Quantum Computers. The Radiance 20-qubit system will be made available in both on-premises and cloud environments and will be delivered by the end of 2
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom